Search ↗

Comparison

Sermorelin vs Tesamorelin

Both are GHRH analogs, so the meaningful differences are in kinetics, evidence and regulatory status.

Sermorelin Tesamorelin
Class GHRH analogs GHRH analogs
Evidence Regulator approved Regulator approved
Human trials ~20 ~15
Half-life ~10-20 minutes ~26-38 minutes
Reported range 200-500 mcg 1-2 mg
Frequency Once daily at bedtime Once daily
Routes Subcutaneous Subcutaneous
FDA approved Yes Yes
Research use only No No
Banned in sport Yes Yes
Studied for Growth hormone deficiency diagnosis and paediatric treatment, Age-related GH decline, Sleep quality, Body composition HIV-associated lipodystrophy, Visceral fat reduction, NAFLD research
Reported side effects Injection-site erythema, Flushing, Headache, Transient dizziness Arthralgia, Injection-site reactions, Peripheral oedema, Myalgia, Impaired glucose tolerance

Sermorelin

Sermorelin is a truncated analog of growth-hormone-releasing hormone comprising residues 1-29, the minimum sequence required for receptor activation. It binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of endogenous growth hormone. Because it acts upstream on the pituitary rather than replacing growth hormone directly, release remains subject to negative feedback from somatostatin and IGF-1, which is the usual argument for a lower risk of supraphysiologic exposure than exogenous hGH.

Tesamorelin

Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminus, a modification that resists degradation by dipeptidyl peptidase-4 and extends its half-life relative to native GHRH. It stimulates pituitary release of growth hormone, raising IGF-1 and preferentially reducing visceral adipose tissue. The visceral-fat selectivity seen in the HIV lipodystrophy trials is the basis of its approval and the reason it is studied separately from other secretagogues.

Sermorelin vs Tesamorelin: common questions

What is the difference between Sermorelin and Tesamorelin?

Both are GHRH analogs. Sermorelin: The first 29 amino acids of endogenous growth-hormone-releasing hormone, and the shortest fragment that retains full biological activity. Tesamorelin: A stabilised GHRH analog and the only growth-hormone secretagogue with a current FDA approval for a body-composition indication.

Which has stronger evidence, Sermorelin or Tesamorelin?

They sit at the same evidence level: regulator approved. Sermorelin has about 20 human studies and Tesamorelin about 15.

Are Sermorelin and Tesamorelin FDA approved?

Both are FDA approved. Sermorelin: Diagnostic assessment of pituitary GH secretory capacity (Geref); Treatment of idiopathic growth hormone deficiency in children with growth failure (Geref, approved 1997; discontinued by the manufacturer in 2008, not for safety reasons). Tesamorelin: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

References

Regulatory and primary sources

  1. PubChem compound record (CID 16132413) ↗ · structure, identifiers, synonyms
  2. DailyMed: FDA-approved labeling for Sermorelin ↗ · indications, dosing, warnings as approved
  3. FDA Drugs@FDA database ↗ · approval history
  4. WADA Prohibited List ↗ · current year
  5. CAS Registry Number 86168-78-7 ↗ · chemical identity
  6. PubChem compound record (CID 16137828) ↗ · structure, identifiers, synonyms
  7. DailyMed: FDA-approved labeling for Tesamorelin ↗ · indications, dosing, warnings as approved
  8. FDA Drugs@FDA database ↗ · approval history
  9. CAS Registry Number 218949-48-5 ↗ · chemical identity

Published literature

  1. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  2. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  3. Memdouh S, Gavrilović I, Ng K, et al.. Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug Test Anal 2021.PubMed 34665524 · doi:10.1002/dta.3183
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?.Clin Interv Aging 2006.PubMed 18046908 · doi:10.2147/ciia.2006.1.4.307
  5. Ramirez G, Herrera R, Pineda D, et al.. The effects of high altitude on hypothalamic-pituitary secretory dynamics in men.Clin Endocrinol (Oxf) 1995.PubMed 7641401 · doi:10.1111/j.1365-2265.1995.tb01887.x
  6. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
  7. Popovic V, Pekic S, Golubicic I, et al.. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.J Clin Endocrinol Metab 2002.PubMed 11994347 · doi:10.1210/jcem.87.5.8485
  8. Saenger P, Pescovitz OH, Bercu BB, et al.. Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone.Endocrine 2001.PubMed 11572326 · doi:10.1385/ENDO:15:1:051
  9. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  10. Badran AS, Helal A, Shata KS, et al.. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.Obes Res Clin Pract 2026.PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
  11. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs 2011.PubMed 21668043 · doi:10.2165/11202240-000000000-00000
  12. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.Ann Pharmacother 2012.PubMed 22298602 · doi:10.1345/aph.1Q629
  13. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  14. Corley MJ, Letendre SL, Nightingale S. CROI 2024: Neuropsychiatric Complications in People With HIV.Top Antivir Med 2024.PubMed 39746672

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.